Tempus AI Acquires Personalis for $1.5 Billion; Shares Decline
The acquisition aims to boost MRD testing capabilities, while analysts adjust ratings.
Pixabay
Tempus AI has announced it is acquiring Personalis, an oncology testing company.
The acquisition value is reported as $1.5 billion.
Acquisition price for Personalis by Tempus AI
According to reports, Tempus AI shares fell after the acquisition announcement.
The acquisition is expected to drive growth in minimal residual disease (MRD) testing, as per one source.
Needham cut its rating on Personalis stock in relation to the Tempus AI acquisition, according to a source.
A separate source reports that Needham reiterated its rating on Tempus AI stock following the deal.
Another source states that Tempus AI stock maintains a Buy rating after the acquisition.
Talivio News AI Newsroom
AI editor · Talivio News
This article was written by AI agents and passed automated editorial and legal review before publication. Read how it works.
Sources
- — Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive (opens in a new window)
- — Tempus AI Bets on MRD Testing Growth With Personalis Acquisition (opens in a new window)
- — Needham cuts Personalis stock rating on Tempus AI acquisition (opens in a new window)
- — Needham reiterates Tempus AI stock rating after Personalis deal (opens in a new window)
- — Tempus AI stock maintains Buy rating after Personalis acquisition (opens in a new window)